NASDAQ:OBIO Orchestra BioMed (OBIO) Stock Price, News & Analysis → If you have $2,500 bucks… check this out (From DTI) (Ad) Free OBIO Stock Alerts $4.39 -0.05 (-1.13%) (As of 04/26/2024 08:53 PM ET) Add Compare Share Share Today's Range$4.36▼$4.5950-Day Range$4.39▼$7.1252-Week Range$4.22▼$20.19Volume24,200 shsAverage Volume48,869 shsMarket Capitalization$157.07 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Orchestra BioMed alerts: Email Address Orchestra BioMed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside287.2% Upside$17.00 Price TargetShort InterestBearish3.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.66) to ($1.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.75 out of 5 starsMedical Sector838th out of 916 stocksSurgical & Medical Instruments Industry85th out of 93 stocks 3.5 Analyst's Opinion Consensus RatingOrchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOrchestra BioMed has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.75% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 17.6, which indicates bearish sentiment.Change versus previous monthShort interest in Orchestra BioMed has recently decreased by 2.88%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldOrchestra BioMed does not currently pay a dividend.Dividend GrowthOrchestra BioMed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OBIO. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Orchestra BioMed this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for OBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Orchestra BioMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchestra BioMed insiders have not sold or bought any company stock.Percentage Held by Institutions53.55% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.66) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchestra BioMed is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchestra BioMed is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchestra BioMed has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. About Orchestra BioMed Stock (NASDAQ:OBIO)Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Read More OBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OBIO Stock News HeadlinesApril 29, 2024 | americanbankingnews.comOrchestra BioMed (OBIO) and The Competition Head to Head SurveyApril 27, 2024 | americanbankingnews.comContrasting Orchestra BioMed (OBIO) & Its RivalsApril 29, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 24, 2024 | americanbankingnews.comReviewing Orchestra BioMed (OBIO) & The CompetitionApril 20, 2024 | americanbankingnews.comCritical Review: Orchestra BioMed (OBIO) & Its PeersMarch 31, 2024 | msn.comOrchestra BioMed: Continuing the Momentum into a Promising FutureMarch 31, 2024 | msn.comOrchestra BioMed Bolsters Board with Healthcare Industry Veteran David PacittiMarch 29, 2024 | finance.yahoo.comOrchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagApril 29, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical DataMarch 27, 2024 | investorplace.comOBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023March 27, 2024 | globenewswire.comOrchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateMarch 26, 2024 | globenewswire.comOrchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of DirectorsMarch 11, 2024 | msn.comOrchestra BioMed's AVIM Therapy Demonstrates Promising Results in Controlling HypertensionMarch 7, 2024 | globenewswire.comOrchestra BioMed to Participate in Upcoming Investor ConferencesMarch 6, 2024 | globenewswire.comOrchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker PatientsFebruary 16, 2024 | finance.yahoo.comWhy Orchestra BioMed (OBIO) Might Surprise This Earnings SeasonJanuary 19, 2024 | benzinga.comOrchestra BioMed Hldgs Stock (NASDAQ:OBIO), Short Interest ReportJanuary 19, 2024 | msn.comJefferies starts Orchestra BioMed at buy, cites lead program opportunitiesJanuary 16, 2024 | morningstar.comOrchestra BioMed Holdings Inc OBIOJanuary 8, 2024 | sg.finance.yahoo.comSilicon Box Accelerates Industry Leadership With Production Commencement at its World Leading Advanced Packaging Facility and Series B FundraisingJanuary 3, 2024 | finance.yahoo.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has caught the attention of hedge funds investors who hold a sizeable 28% stakeDecember 18, 2023 | msn.comBATL, SNCR and BVN are among pre market gainersNovember 16, 2023 | finanznachrichten.deOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Bicycle Therapeutics (BCYC)November 14, 2023 | uk.finance.yahoo.comOrchestra BioMed Holdings, Inc. (OBIO)November 13, 2023 | finance.yahoo.comOrchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business UpdateSee More Headlines Receive OBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/28/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:OBIO CUSIPN/A CIK1814114 Weborchestrabiomed.com Phone646-597-6980FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$20.00 Low Stock Price Target$14.00 Potential Upside/Downside+287.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,120,000.00 Net Margins-1,779.71% Pretax Margin-1,779.71% Return on Equity-58.32% Return on Assets-41.47% Debt Debt-to-Equity RatioN/A Current Ratio7.95 Quick Ratio7.94 Sales & Book Value Annual Sales$2.76 million Price / Sales56.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book2.31Miscellaneous Outstanding Shares35,780,000Free FloatN/AMarket Cap$157.07 million OptionableNot Optionable Beta0.15 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. David P. Hochman (Age 49)Founder, Chairman of the Board of Directors & CEO Comp: $942kMr. Darren R. Sherman (Age 53)Founder, President, COO & Director Comp: $787kMr. Andrew Lawrence Taylor M.B.A. (Age 53)Chief Financial Officer Comp: $326.37kMr. William Reed Little (Age 52)Executive VP of Corporate Development & Strategy Dr. Yuval Hay Mika D.Sc (Age 65)Ph.D., GM & CTO of Bioelectronic Therapies Dr. George Papandreou Ph.D. (Age 59)GM & Senior VP of Focal Therapies Dr. Hans-Peter Stoll M.D.Ph.D., Chief Clinical OfficerDr. Avraham Matityahu Fischer M.D. (Age 68)Senior Vice President of Medical Affairs & Innovation Mr. Bob LaughnerSenior Vice President of Regulatory & QualityMr. Juan LorenzoSenior Vice President of Product DevelopmentMore ExecutivesKey CompetitorsQuipt Home MedicalNASDAQ:QIPTAlpha Tau MedicalNASDAQ:DRTSClearPoint NeuroNASDAQ:CLPTDelcath SystemsNASDAQ:DCTHProfound MedicalNASDAQ:PROFView All CompetitorsInstitutional OwnershipNew York State Common Retirement FundSold 7,931 shares on 2/1/2024Ownership: 0.010%View All Institutional Transactions OBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Orchestra BioMed stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OBIO shares. View OBIO analyst ratings or view top-rated stocks. What is Orchestra BioMed's stock price target for 2024? 2 Wall Street research analysts have issued 12-month price objectives for Orchestra BioMed's stock. Their OBIO share price targets range from $14.00 to $20.00. On average, they predict the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 287.2% from the stock's current price. View analysts price targets for OBIO or view top-rated stocks among Wall Street analysts. How have OBIO shares performed in 2024? Orchestra BioMed's stock was trading at $9.13 at the beginning of 2024. Since then, OBIO stock has decreased by 51.9% and is now trading at $4.39. View the best growth stocks for 2024 here. When is Orchestra BioMed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our OBIO earnings forecast. How were Orchestra BioMed's earnings last quarter? Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) issued its earnings results on Wednesday, March, 27th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.01. The company had revenue of $0.26 million for the quarter, compared to analysts' expectations of $1 million. Orchestra BioMed had a negative trailing twelve-month return on equity of 58.32% and a negative net margin of 1,779.71%. How do I buy shares of Orchestra BioMed? Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OBIO) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
